Management of intradialytic hypertension: current evidence and future perspectives

Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Greece

Correspondence to Pantelis Sarafidis, MD, MSc, PhD, Department of Nephrology, Aristotle University of Thessaloniki, Hippokration Hospital, Konstantinoupoleos 49, 54642, Thessaloniki, Greece. Tel: +30 2310 892030; e-mail: [email protected]

Abbreviations: ABPM, ambulatory blood pressure monitoring; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-II receptor blockers; BP, blood pressure; CCBs, calcium channel blockers; CKD, chronic kidney disease; ESKD, end-stage kidney disease; IDH, intradialytic hypertension; KDIGO, Kidney Disease Improving Global Outcomes; LBNP, lower body negative pressure; MSNA, muscle sympathetic nerve activity; MRAs, mineralocorticoid receptor antagonists; PRA, plasma renin activity; RAAS, renin–angiotensin–aldosterone system; RRT, renal replacement therapy; SNS, sympathetic nervous system

Received 19 February, 2022

Revised 30 May, 2022

Accepted 22 June, 2022

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).

留言 (0)

沒有登入
gif